Deoxyribonuclease I

Directory of Therapeutic Enzymes

Volumn , Issue , 2005, Pages 97-116

  Sanders, Niek N ^a   De Smedt, Stefaan C ^a   Demeester, Joseph ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85179198246     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420038378-5     Document Type: Chapter

References (170)

1. Kreuder, V., et al., Isolation, characterization and crystallization of deoxyribonuclease-I from bovine and rat parotid-gland and its interaction with rabbit skeletal-muscle actin, Eur. J. Biochem., 139, 389-400, 1984.
2. Shiokawa, D. and Tanuma, S., Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis, Biochemistry, 40, 143-152, 2001.
3. Evans, C.J. and Aguilera, R.J., DNase II: Genes, enzymes and function, Gene, 322, 1-15, 2003.
4. Nadano, D., Yasuda, T., and Kishi, K., Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method, Clin. Chem., 39, 448-452, 1993.
5. Zanotti, S., et al., Localization of deoxyribonuclease-I gene transcripts and protein in rat-tissues and its correlation with apoptotic cell elimination, Histochem. Cell Biol., 103, 369-377, 1995.
6. Napirei, M., et al., Expression pattern of the deoxyribonuclease 1 gene: Lessons from the Dnase 1 knockout mouse, Biochem. J., 380, 929-937, 2004.
7. McCarty, M., Purification and properties of deoxyribonuclease isolated from beef pancreas, J. Gen. Physiol., 29, 123-139, 1946.
8. Armstrong, J.B. and White, J.C., Liquefaction of viscous purulent exudates by deoxyribonuclease, Lancet, 259, 739-742, 1950.
9. Salomon, A., Herchfus, J.A., and Segal, M.S., Aerosols of pancreatic dornase in bronchopulmonary disease, Ann. Allergy, 12, 71, 1954.
10. Elmes, P.C. and White, J.C., Deoxyribonuclease in the treatment of purulent bronchitis, Thorax, 8, 295-300, 1953.
11. Spier, R., Witebsky, E., and Paine, J., Aerosolized pancreatic dornase and antibiotics in pulmonary infections: Use in patients with postoperative and nonoperative infections, JAMA, 178, 878, 1961.
12. Shak, S., et al., Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum, Proc. Natl. Acad. Sci. USA, 87, 9188-9192, 1990.
13. Parker, R.H., Wilcox, W.D., and Dietrich, T.S., Toxicity of intrathecally administered pancreatic dornase, JAMA, 192, 169, 1965.
14. Raskin, P., Bronchospasm after inhalation of pancreatic dornase, Am. Rev. Respir. Dis., 98, 697-698, 1968.
15. Liao, T.H., et al., Bovine pancreatic deoxyribonuclease-A. Isolation of cyanogen bromide peptides-Complete covalent structure of polypeptide-chain, J. Biol. Chem., 248, 1489-1495, 1973.
16. Gonda, I., Inhalation therapy with recombinant human deoxyribonuclease I, Adv. Drug Deliv. Rev., 19, 37-46, 1996.
17. Oefner, C. and Suck, D., Crystallographic refinement and structure of DNase-I at 2Å resolution, J. Mol. Biol., 192, 605-632, 1986.
18. Lazarus, R.A., Deoxyribonucleases, in Wiley Encyclopedia of Molecular Medicine, T.E. Creighton, Ed., Wiley, New York, 2002, pp. 1025-1028.
19. Nishikawa, A. and Mizuno, S., The efficiency of N-linked glycosylation of bovine DNase I depends on the Asn-Xaa-Ser/Thr sequence and the tissue of origin, Biochem. J., 355, 245-248, 2001.
20. Cacia, J., et al., Human DNase I contains mannose 6-phosphate and binds the cation-independent mannose 6-phosphate receptor, Biochemistry, 37, 15154-15161, 1998.
21. Chen, B., et al., Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states, J. Pharm. Sci., 88, 477-482, 1999.
22. Price, P.A., Characterization of Ca_and Mg_binding to bovine pancreatic deoxyribonuclease A, J. Biol. Chem., 247, 2895-2899, 1972.
23. Poulos, T.L. and Price, P.A., Some effects of calcium ions on structure of bovine pancreatic deoxyribonuclease A, J. Biol. Chem., 247, 2900-2904, 1972.
24. Chan, H.K., Au-Yeung, K.L., and Gonda, I., Eu-Yeung, K.L., and Gonda, I., Effects of additives on heat denaturation of rhDNase in solutions, Pharm. Res., 13, 756-761, 1996.
25. Price, P.A., Stein, W.H., and Moore, S., Effect of divalent cations on the reduction and re-formation of the disulfide bonds of deoxyribonuclease, J. Biol. Chem., 244, 929-932, 1969.
26. Chen, C.Y., Lu, S.C., and Liao, T.H., The distinctive functions of the two structural calcium atoms in bovine pancreatic deoxyribonuclease, Protein Sci., 11, 659-668, 2002.
27. Jones, S.J., Worrall, A.F., and Connolly, B.A., Site-directed mutagenesis of the catalytic residues of bovine pancreatic deoxyribonuclease I, J. Mol. Biol., 264, 1154-1163, 1996.
28. Pan, C.Q., et al., Mutational analysis of human DNase I at the DNA binding interface:Implications for DNA recognition, catalysis, and metal ion dependence, Protein Sci., 7, 628-636, 1998.
29. Suck, D., Oefner, C., and Kabsch, W., Three-Dimensional structure of bovine pancreatic DNase I at 2.5 Å resolution, EMBO J., 3, 2423-2430, 1984.
30. Pan, C.Q. and Lazarus, R.A., Hyperactivity of human DNase I variants-Dependence on the number of positively charged residues and concentration, length, and environment of DNA, J. Biol. Chem., 273, 11701-11708, 1998.
31. Campbell, V.W. and Jackson, D.A., The effect of divalent cations on the mode of action of DNase I-The initial reaction products produced from covalently closed circular DNA, J. Biol. Chem., 255, 3726-3735, 1980.
32. Suck, D., DNA recognition by DNase I, J. Mol. Recognit., 7, 65-70, 1994.
33. Funakoshi, A., et al., Purification and properties of human pancreatic deoxyribonuclease I, J. Biochem., 82, 1771-1777, 1977.
34. Weston, S.A., Lahm, A., and Suck, D., X-ray structure of the DNase I-d(GGTATACC)2 complex at 2.3 Å resolution, J. Mol. Biol., 226, 1237-1256, 1992.
35. Lahm, A. and Suck, D., DNase I-induced DNA conformation 2 Å structure of a DNase I-octamer complex, J. Mol. Biol., 222, 645-667, 1991.
36. Doherty, A.J., Worrall, A.F., and Connolly, B.A., The roles of arginine 41 and tyrosine 76 in the coupling of DNA recognition to phosphodiester bond-cleavage by DNase I: A study using sitedirected mutagenesis, J. Mol. Biol., 251, 366-377, 1995.
37. Worrall, A.F. and Connolly, B.A., The chemical synthesis of a gene coding for bovine pancreatic DNase I and its cloning and expression in Escherichia coli, J. Biol. Chem., 265, 21889-21895, 1990.
38. Suck, D. and Oefner, C., Structure of DNase I at 2.0 Å resolution suggests a mechanism for binding to and cutting DNA, Nature, 321, 620-625, 1986.
39. Liao, T.H. and Hsieh, J.C., Hydrolysis of para-nitrophenyl phenylphosphonate catalyzed by bovine pancreatic deoxyribonuclease, Biochem. J., 255, 781-787, 1988.
40. Pan, C.Q., Sinicropi, D.V., and Lazarus, R.A., Engineered properties and assays for human DNase I mutants, in Methods in Molecular Biology, Vol. 160, Shein, C.H., Ed., Humana Press Inc., Totowa, 2001, pp. 309-321.
41. Sinicropi, D.V. and Lazarus, R.A., Assays for human DNase I activity in biological matrices, in Methods in Molecular Biology, Vol. 160, Shein, C.H., Ed., Humana Press Inc., Totowa, 2001, pp. 325-333.
42. Kunitz, M., Crystalline desoxyribonuclease. 1. Isolation and general properties; spectrophotometric method for the measurement of desoxyribonuclease activity, J. Gen. Physiol., 33, 349-362, 1950.
43. Sinicropi, D., et al., Colorimetric determination of DNase I activity with a DNA-methyl green substrate, Anal. Biochem., 222, 351-358, 1994.
44. Kurnick, N.B., The determination of deoxyribonuclease activity by methyl green; Application to serum, Arch. Biochem., 29, 41-53, 1950.
45. Choi, S.J. and Szoka, F.C., Fluorometric determination of deoxyribonuclease I activity with PicoGreen, Anal. Biochem., 281, 95-97, 2000.
46. Wine, J.J., The genesis of cystic fibrosis lung disease, J. Clin. Invest., 103, 309-312, 1999.
47. Ratjen, F. and Doring, G., Cystic fibrosis, Lancet, 361, 681-689, 2003.
48. Sheppard, D.N. and Welsh, M.J., Structure and function of the CFTR chloride channel, Physiol. Rev., 79, S23-S45, 1999.
49. Konstan, M.W. and Berger, M., Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology, Pediatr. Pulmonol., 24, 137-142, 1997.
50. Lethem, M.I., et al., The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum, Eur. Respir. J., 3, 19-23, 1990.
51. Picot, R., Das, I., and Reid, L., Pus, deoxyribonucleic acid, and sputum viscosity, Thorax, 33, 235-242, 1978.
52. Vasconcellos, C.A., et al., Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin, Science, 263, 969-971, 1994.
53. Robinson, M. and Bye, P.T.B., Mucociliary clearance in cystic fibrosis, Pediatr. Pulmonol., 33, 293-306, 2002.
54. Shah, P.L., et al., In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis, Thorax, 51, 119-125, 1996.
55. Puchelle, E., et al., Effects of rhDNase on purulent airways secretions in chronic bronchitis, Eur. Respir. J., 9, 765-769, 1996.
56. Sanders, N.N., et al., Structural alterations of gene complexes by cystic fibrosis sputum, Am. J. Respir. Crit. Care Med., 164, 486-493, 2001.
57. Zahm, J.M., et al., Dose dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus, Eur. Respir. J., 8, 381-386, 1995.
58. Deneuville, E., et al., Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients, Am. J. Respir. Crit. Care Med., 156, 166-172, 1997.
59. King, M., et al., Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I, Am. J. Respir. Crit. Care Med., 156, 173-177, 1997.
60. Zahm, J.M., et al., Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile, Am. J. Respir. Crit. Care Med., 157, 1779-1784, 1998.
61. Ratjen, F. and Tummler, B., Comparison of the in vitro and in vivo response to inhaled DNase in patients with cystic fibrosis, Thorax, 54, 91, 1999.
62. Bryson, H.M. and Sorkin, E.M., Dornase alfa-A review of its pharmacological properties and therapeutic potential in cystic fibrosis, Drugs, 48, 894-896, 1994.
63. Shak, S., Aerosolized recombinant human DNase I for the treatment of cystic fibrosis, Chest, 107, 65S-70S, 1995.
64. Hodson, M.E. and Shah, P.L., DNase trials in cystic fibrosis, Eur. Respir. J., 8, 1786-1791, 1995.
65. Shah, P.L. and Hodson, M.E., Dornase alfa-A practical guide to patient selection and drug use in cystic fibrosis, Biodrugs, 8, 439-445, 1997.
66. Davies, J., et al., Retrospective review of the effects of rhDNase in children with cystic fibrosis, Pediatr. Pulmonol., 23, 243-248, 1997.
67. Christopher, F., et al., rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease, J. Clin. Pharm. Ther., 24, 415-426, 1999.
68. Hodson, M.E., et al., Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis, Pediatr. Pulmonol., 36, 427-432, 2003.
69. Hubbard, R.C., et al., A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis, New Engl. J. Med., 326, 812-815, 1992.
70. Ramsey, B.W., et al., Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis, Am. Rev. Respir. Dis., 148, 145-151, 1993.
71. Ranasinha, C., et al., Efficacy and safety of short-term administration of aerosolized recombinant human DNaseI in adults with stable stage cystic fibrosis, Lancet, 342, 199-202, 1993.
72. Shah, P.I., et al., Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease-A short-term, double-blind study followed by 6 months open-label treatment, Eur. Resp. J., 8, 954-958, 1995.
73. Wilmott, R.W., et al., Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations, Am. J. Respir. Crit. Care Med., 153, 1914-1917, 1996.
74. Fuchs, H.J., et al., Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis, New Engl. J. Med., 331, 637-642, 1994.
75. Shah, P.L., et al., 2 Years Experience with recombinant human DNase-I in the treatment of pulmonary disease in cystic fibrosis, Respir. Med., 89, 499-502, 1995.
76. McCoy, K., Hamilton, S., and Johnson, C., Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease, Chest, 110, 889-895, 1996.
77. Geller, D.E., et al., Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis, Pediatr. Pulmonol., 25, 83-87, 1998.
78. Quan, J.M., et al., A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities, J. Pediatr., 139, 813-820, 2001.
79. Robinson, P.J., Dornase alfa in early cystic fibrosis lung disease, Pediatr. Pulmonol., 34, 237-241, 2002.
80. Harms, H.K., et al., Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease, Pediatr. Pulmonol., 26, 155-161, 1998.
81. Johnson, C.A., et al., Estimating effectiveness in an observational study: A case study of dornase alfa in cystic fibrosis, J. Pediatr., 134, 734-739, 1999.
82. Furuya, M.E.Y., et al., Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis, Arch. Med. Res., 32, 30-34, 2001.
83. Shah, P.L., et al., A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period, Respiration, 68, 160-164, 2001.
84. Suri, R., et al., Comparison of hypertonic saline and alternate day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: A randomised trial, Lancet, 358, 1316-1321, 2001.
85. Paul, K., et al., Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis, Am. J. Respir. Crit. Care Med., 169, 719-725, 2004.
86. Wagener, J.S., et al., Aerosol delivery and safety of recombinant human deoxryribonuclease in young children with cystic fibrosis: A bronchoscopic study, J. Pediatr., 133, 486-491, 1998.
87. Aitken, M.L., et al., Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis-A phase 1 study, JAMA, 267, 1947-1951, 1992.
88. Pulmozyme® Product monograph Genentech Inc., South San Franscisco, 2001.
89. Shah, P.L., et al., The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis, Eur. Resp. J., 9, 531-534, 1996.
90. Cantin, A.M., DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice, Am. J. Respir. Crit. Care Med., 157, 464-469, 1998.
91. Perks, B. and Shute, J.K., DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa-In vitro effects of mucolytics, Am. J. Respir. Crit. Care Med., 162, 1767-1772, 2000.
92. Paul, K., et al., Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis, Am. J. Respir. Crit. Care Med., 169, 719-725, 2004.
93. Henry, R.L., et al., Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis, Pediatr. Pulmonol., 26, 97-100, 1998.
94. Suri, R., et al., Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis, Am. J. Respir. Crit. Care Med., 166, 352-355, 2002.
95. Green, J.D., Pharmacotoxicological Expert Report-PulmozymeTM rhDNase Genentech, Inc., Hum. Exp. Toxicol., 13, S1-42, 1994.
96. Sinicropi, M.W., et al., Sputum pharmacodynamics and pharmacokinetics of recombinant DNase I in cystic fibrosis, Am. J. Respir. Crit. Care Med., 149, A671, 1994.
97. Robinson, M., et al., Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis, Pediatr. Pulmonol., 30, 16-24, 2000.
98. Mohler, M., et al., Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein, Drug Metab. Dispos., 21, 71-75, 1993.
99. Fiel, S.B., et al., Comparison of 3 jet nebulizer aerosol delivery systems used to administer recombinant human DNase-I to patients with cystic fibrosis, Chest, 108, 153-156, 1995.
100. Shah, P.L., et al., An evaluation of two aerosol delivery systems for rhDNase, Eur. Respir. J., 10, 1261-1266, 1997.
101. Diot, P., et al., RhDNase I aerosol deposition and related factors in cystic fibrosis, Am. J. Respir. Crit. Care Med., 156, 1662-1668, 1997.
102. Chan, H.K., et al., Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery, Pharm. Res., 14, 431-437, 1997.
103. Chan, H.K. and Gonda, I., Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (RhDNase), J. Pharm. Sci., 87, 647-654, 1998.
104. Bustami, R.T., et al., Generation of fine powders of recombinant human deoxyribonuclease using the aerosol solvent extraction system, Pharm. Res., 20, 2028-2035, 2003.
105. Zijlstra, G.S., et al., Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis, Expert Rev. Pharmacoeconomics Outcomes Res., 4, 49-59, 2004.
106. Davis, P.B., Evolution of therapy for cystic fibrosis, New Engl. J. Med., 331, 672-673, 1994.
107. Davies, J., et al., Retrospective review of the effects of rhDNase in children with cystic fibrosis, Pediatr. Pulmonol., 23, 243-248, 1997.
108. Milla, C.E., Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis, Thorax, 53, 1014-1017, 1998.
109. Cobos, N., et al., DNase use in the daily care of cystic fibrosis: Who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres, Eur. J. Pediatr., 159, 176-181, 2000.
110. Suri, R., et al., Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis, Pediatr. Pulmonol., 37, 305-310, 2004.
111. Sanders, N.N., De Smedt, S.C., and Demeester, J., Therapeutic Compositions for the Treatment of a Respiratory Tract Disease, Universiteit Gent, Patent WO02083167, 2002.
112. Lazarides, E. and Lindberg, U., Actin is the naturally occurring inhibitor of deoxyribonuclease I, Proc. Natl. Acad. Sci., USA, 71, 4742-4746, 1974.
113. Ulmer, J.S., et al., Engineering actin-resistant human DNase I for treatment of cystic fibrosis, Proc. Natl. Acad. Sci., USA, 93, 8225-8229, 1996.
114. Mannherz, H.G., et al., The interaction of bovine pancreatic deoxyribonuclease I and skeletal muscle actin, Eur. J. Biochem., 104, 367-379, 1980.
115. Kabsch, W., et al., Atomic structure of the actin: DNase I complex, Nature, 347, 37-44, 1990.
116. McLaughlin, P.J. and Weeds, A.G., Actin binding protein complexes at atomic resolution, Annu. Rev. Biophys. Biomol. Struct., 24, 643-675, 1995.
117. Mannherz, H.G. and Rohr, G., 5'-Nucleotidase reverses the inhibitory action of actin on pancreatic deoxyribonuclease I, FEBS Lett., 95, 284-289, 1978.
118. Rohr, G. and Mannherz, H.G., The activation of actin: DNase I complex with rat liver plasma membranes. The possible role of 5'-nucleotidase, FEBS Lett., 99, 351-356, 1979.
119. Davoodian, K., et al., Gelsolin activates DNase I in vitro and in cystic fibrosis sputum, Biochemistry, 36, 9637-9641, 1997.
120. Zahm, J.M., et al., Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions, Am. J. Respir. Crit. Care Med., 163, 1153-1157, 2001.
121. Baron, W.F., et al., Cloning and characterization of an actin-resistant DNase I-like endonuclease secreted by macrophages, Gene, 215, 291-301, 1998.
122. Shiokawa, D. and Tanuma, S., DLAD, a novel mammalian divalent cation-independent endonuclease with homology to DNase II, Nucleic Acids Res., 27, 4083-4089, 1999.
123. Krieser, R.J., et al., The cloning, genomic structure, localization, and expression of human deoxyribonuclease II, Gene, 269, 205-216, 2001.
124. Ratjen, F., Dornase in non-CF, Pediatr. Pulmonol., 26 (Suppl.), 154-155, 2004.
125. Gershan, W.M., et al., Resolution of chronic atelectasis in a child with asthma after aerosolized recombinant human DNase, Pediatr. Pulmonol., 18, 268-269, 1994.
126. Touleimat, B.A., Conoscenti, C.S., and Fine, J.M., Recombinant human DNase in management of lobar atelectasis due to retained secretions, Thorax, 50, 1319-1321, 1995.
127. Voelker, K.G., Chetty, K.G., and Mahutte, C.K., Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase, Intensive Care Med., 22, 582-584, 1996.
128. Greally, P., Human recombinant DNase for mucus plugging in status asthmaticus, Lancet, 346, 1423-1424, 1995.
129. Durward, A., Forte, V., and Shemie, S.D., Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus, Crit. Care Med., 28, 560-562, 2000.
130. El-Hassan, N.O., et al., Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates, Pediatrics, 108, 468-470, 2001.
131. Merkus, P.J.F.M., et al., DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis, Eur. Respir. J., 18, 734-737, 2001.
132. Desai, M., Weller, P.H., and Spencer, D.A., Clinical benefit from nebulized human recombinant DNase in Kartagener’s syndrome, Pediatr. Pulmonol., 20, 307-308, 1995.
133. ten Berge, M., et al., DNase treatment in primary ciliary dyskinesia-Assessment by nocturnal pulse oximetry, Pediatr. Pulmonol., 27, 59-61, 1999.
134. Nasr, S.Z., et al., Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis, Chest, 120, 203-208, 2001.
135. Simpson, G., Roomes, D., and Reeves, B., Successful treatment of empyema thoracis with human recombinant deoxyribonuclease, Thorax, 58, 365-366, 2003.
136. Wills, P.J., et al., Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability, Am. J. Respir. Crit. Care Med., 154, 413-417, 1996.
137. Hudson, T.J., Dornase in treatment of chronic bronchitis, Ann. Pharmacother., 30, 674-675, 1996.
138. O’Donnell, A.E., et al., Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I, rhDNase Study Group, Chest, 113, 1329-1334, 1998.
139. Rubin, B.K., Who will benefit from DNase? Pediatr. Pulmonol., 27, 3-4, 1999.
140. Vanholder, R., et al., The pathophysiology of lupus erythematosus, Eur. J. Dermatol., 8, 4-7, 1998.
141. Bickerstaff, M.C.M., et al., Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity, Nat. Med., 5, 694-697, 1999.
142. Botto, M., et al., Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies, Nat. Genet., 19, 56-59, 1998.
143. Manderson, A.P., Botto, M., and Walport, M.J., The role of complement in the development of systemic lupus erythematosus, Annu. Rev. Immunol., 22, 431-456, 2004.
144. Macanovic, M. and Lachmann, P.J., Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay, Clin. Exp. Immunol., 108, 220-226, 1997.
145. Napirei, M., et al., Features of systemic lupus erythematosus in Dnase1-deficient mice, Nat. Genet., 25, 177-181, 2000.
146. Lachmann, P.J., Lupus and desoxyribonuclease, Lupus, 12, 202-206, 2003.
147. Yasutomo, K., et al., Mutation of DNASE1 in people with systemic lupus erythematosus, Nat. Genet., 28, 313-314, 2001.
148. Puccetti, A., et al., Anti-DNA antibodies bind to DNase I, J. Exp. Med., 181, 1797-1804, 1995.
149. Yeh, T.M., et al., Deoxyribonuclease-inhibitory antibodies in systemic lupus erythematosus, J. Biomed. Sci., 10, 544-551, 2003.
150. Lachmann, P.J., Allergic reactions, connective tissue, and disease, Sci. Basis Med. Annu. Rev., 36-58, 1967.
151. Macanovic, M., et al., The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone, Clin. Exp. Immunol., 106, 243-252, 1996.
152. Verthelyi, D., et al., DNAse treatment does not improve the survival of lupus prone (NZB × NZW) F1 mice, Lupus, 7, 223-230, 1998.
153. Davis, J.C., et al., Recombinant human Dnase I (rhDNase) in patients with lupus nephritis, Lupus, 8, 68-76, 1999.
154. Prince, W.S., et al., Pharmacodynamics of recombinant human DNase I in serum, Clin. Exp. Immunol., 113, 289-296, 1998.
155. Clark, M.G., Topical Ointment Composition, US. Patent 4005191, 1977.
156. Schwarz, N., Wound cleansing with the enzyme combination fibrinolysin/deoxy-ribonuclease, Fortschr. Med., 99, 978-980, 1981.
157. Westerhof, W., et al., Controlled double-blind trial of fibrinolysin-deoxyribonuclease (Elase) solution in patients with chronic leg ulcers who are treated before autologous skin-grafting, J. Am. Acad. Dermatol., 17, 32-39, 1987.
158. Toriyabe, S., Saito, H., and Sakurai, R., Use of a food wrap as a dressing material, Adv. Skin Wound Care, 6, 405-406, 1999.
159. Romancalderon, J., Treatment of 2nd and 3rd degree burns-Comparison of effects of proteolytic-enzyme combination and silver-nitrate, Curr. Ther. Res., 32, 305-311, 1982.
160. Mekkes, J.R., et al., In vitro tissue digesting properties of krill enzymes compared with fibrinolysin/DNAse, papain and placebo, Int. J. Biochem. Cell Biol., 29, 703-706, 1997.
161. Falabella, A.F., et al., The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity, J. Am. Acad. Dermatol., 39, 737-740, 1998.
162. Mekkes, J.R., Zeegelaar, J.E., and Westerhof, W., Quantitative and objective evaluation of wound debriding properties of collagenase and fibrinolysin/desoxyribonuclease in a necrotic ulcer animal model, Arch. Dermatol. Res., 290, 152-157, 1998.
163. Linardou, H., Epenetos, A.A., and Deonarain, M.P., A recombinant cytotoxic chimera based on mammalian deoxyribonuclease I, Int. J. Cancer, 86, 561-569, 2000.
164. Ben-Yehudah, A., et al., Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein, Clin. Cancer Res., 9, 1179-1190, 2003.
165. Shak, S., Human DNase, Genentech, Patent WO9007572, 1989.
166. Mather, J.P. and Tsao, M.C., Method for Culturing Chinese Hamster Ovary Cells to Improve Production of Recombinant Proteins, Genentech, U.S. Patent 5122469, 1992.
167. Chan, H.K., et al., DNase Liquid Solutions, Genentech, U.S. Patent Application 20030054532, 2003.
168. Frenz, J., Steven, J., and Sliwkowski, M.B., Purified Forms of DNase, Genentech, Patent WO9325670, 1993.
169. Hsieh, S.Y., et al., Aberrant caspase-activated DNase (CAD) transcripts in human hepatoma cells, Br. J. Cancer, 88, 210-216, 2003.
170. Bairoch A., et al., Swiss-Prot: Juggling between evolution and stability, Brief. Bioinform., 5, 39-55, 2004.